Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (3365)	9/15/2021 9:55:01 PM
From: BioBait	Read Replies (2) \| Respond to of 3557

$3b order. Not too shabby. Order likely limited by manufacturing Need Roche too supply 1/3. Still wishing regeneron could produce more. I’ll take the bet on future orders. Many more variants to come. Vir/GSK could become competitive product. Cov revenue q3 small. Then another large Q4. So, q4 eps $28? Q1. 10 Q2. 28 Q3. 12 Q4. 28 2021. EPS. 78? Maybe a special div $10 at year end. Lol - will never do - more likely give to execs. 2022. >60 ? P/e r 12-15 (15 if future orders for cov continue) 720-900/share